-
1.发明申请公开(公告)号：US20220127343A1
公开(公告)日：2022-04-28
申请号：US17493032
申请日：2021-10-04
Applicant: Janssen Biotech, Inc.
Inventor： Chichi Huang , John Lee , Jill Mooney , Michael Naso
IPC: C07K16/18
Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
-
2.发明申请公开(公告)号：US20190175651A1
公开(公告)日：2019-06-13
申请号：US16215716
申请日：2018-12-11
Applicant: Janssen Biotech, Inc.
Inventor： John Lee , Jill Mooney , Michael Naso
IPC: A61K35/17 , C07K14/78 , C07K14/47 , C07K14/705 , C07K14/715 , A61P35/00 , C12N15/85 , C12N15/90
Abstract: The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.
-
3.发明申请Prostate Specific Membrane Antigen (PSMA) Bispecific Binding Agents and Uses Thereof 审中-公开前列腺特异性膜抗原（PSMA）双特异性结合剂及其用途公开(公告)号：US20160347840A1
公开(公告)日：2016-12-01
申请号：US15148371
申请日：2016-05-06
Applicant: Janssen Biotech, Inc.
Inventor： Glenn Anderson , Rosa Cardoso , Michael Diem , Francois Gaudet , Shalom Goldberg , Benjamin Harman , Linus Hyun , Steven Jacobs , Donna Klein , Yingzhe Li , Jinquan Luo , Ronan McDaid , Jill Mooney , Jennifer Nemeth-Seay , Karyn O'Neil , Steven Pomerantz , Galla Chandra Rao , Tracy Spinka-Doms , Alexey Teplyakov , Leopoldo Luistro , Sheng-Jiun Wu
IPC: C07K16/28 , C07K14/78 , A61K45/06 , C07K16/30 , A61K39/395
CPC classification number: C07K16/2809 , A61K45/06 , A61K47/6803 , A61K47/6869 , A61K49/0045 , A61K49/0058 , A61K2039/505 , C07K14/78 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/53 , C07K2317/55 , C07K2317/70 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C12Y304/17021
Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
Abstract translation: 本文提供了分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段，其中FN3结构域特异性结合人前列腺特异性膜抗原（PSMA）和第二抗原结合位点免疫特异性结合CD3。 还描述了能够编码所提供的融合蛋白的融合蛋白和相关多核苷酸，以及表达所提供的融合蛋白的细胞。 此外，描述了使用所提供的分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段的方法。
-
4.发明授权公开(公告)号：US11161897B2
公开(公告)日：2021-11-02
申请号：US16037340
申请日：2018-07-17
Applicant: Janssen Biotech, Inc.
Inventor： Chichi Huang , John Lee , Jill Mooney , Michael Naso
IPC: C07K16/28 , C07K16/46 , C07K14/735 , A61K39/395 , C07K16/18
Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
-
Patent Agency Ranking
5.发明授权公开(公告)号：US11096998B2
公开(公告)日：2021-08-24
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
IPC: C07K16/00 , C07K16/46 , C07K16/28 , A61K39/00 , C12N15/82 , A61P35/00 , C07K14/525 , C07K14/705 , C07K14/75 , C07K14/78
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
6.发明申请公开(公告)号：US20190330361A1
公开(公告)日：2019-10-31
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
7.发明授权公开(公告)号：US12269870B2
公开(公告)日：2025-04-08
申请号：US17493032
申请日：2021-10-04
Applicant: Janssen Biotech, Inc.
Inventor： Chichi Huang , John Lee , Jill Mooney , Michael Naso
Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
-
8.发明申请公开(公告)号：US20200332255A1
公开(公告)日：2020-10-22
申请号：US16770809
申请日：2018-12-11
Applicant: Janssen Biotech, Inc.
Inventor： John Lee , Jill Mooney , Michael Naso
IPC: C12N5/0783 , C07K16/18 , C07K16/28 , C07K14/725 , C07K14/705 , C12N15/87 , C12N15/86 , A61K35/17
Abstract: The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be per-formed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the hosts immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.
-
9.发明申请公开(公告)号：US20190016789A1
公开(公告)日：2019-01-17
申请号：US16037340
申请日：2018-07-17
Applicant: Janssen Biotech, Inc.
Inventor： Chichi Huang , John Lee , Jill Mooney , Michael Naso
IPC: C07K16/18
Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
